Value of Brachytherapy as Part of Interdisciplinary Therapeutic Concepts for Solid Tumor Lesions – Brachytherapeutic Options and Spectrum of Treatment Results at the Center of Radiology (Department of Radiotherapy - University Hospital of Magdeburg)


1Department of Radiation Therapy, University Hospital, Magdeburg, Germany
2Department of General, Abdominal and Vascular Surgery, University Hospital, Magdeburg, Germany
3Department of Radiology and Nuclear Medicine, University Hospital, Magdeburg, Germany
4Department of Gynecology and Obstetrics, University Hospital, Magdeburg, Germany
5Department of Otorhinolaryngology, University Hospital, Magdeburg, Germany
6University Hospital at Magdeburg, Magdeburg; Germany

*Corresponding author: P Hass, Department of Radiation Therapy, University Hospital, Magdeburg, Germany

Received: November 14, 2016; Accepted: December 22, 2016; Published: December 24, 2016

Abstract

As in many other medical disciplines, a substantial change of paradigms in oncology and oncotherapy can be observed. In particular, for the treatment of solid tumor lesions the former rather rigid approach to differentiate between curative (no detection of distant metastases) and palliative intention (including systemic advancement of tumor disease) has been increasingly overcome. The concept of oligometastases has been getting more and more attention. Oligometastatic status can be classified if in first diagnosis or in follow-up investigation for tumor staging only a few distant metastases are found. According to the former guidelines, this might only lead to initiation of a palliative treatment, in the majority of cases to a systemic type of therapy! Interestingly, there has been substantial evidence that local ablation of the small number of filiae can favorably influence quality of life (the main intent of "palliative care" according to the definition by WHO) and prognosis. However, there are no predictive markers yet such as laboratory parameters, which allow to assess prognosis of a certain tumor stage / disease including oligometastases.

Surgical resection was and is the gold standard of local ablation but only a certain percentage of patients with oligometastases can be approached with surgical intervention since several of them are unresectable from a technical or inoperable from an anesthesiological point of view. In addition to surgical ablation, there have been a number of non- or minimally invasive techniques available such as thermo-, chemo- and radioablading procedures.

This review aims at Brachytherapy (BT) as radioablating method, its indications as part of curative concepts, the possible treatment spectrum shown in detail at the University Hospital of Magdeburg (Germany), and, in particular, indicating what is feasible and achievable from a qualitative and quantitative point of view. Finally, exemplary and representative cases document the potential benefit in radioablation of metastases.

Keywords: Brachytherapy; Radiation Therapy; Interstitial Brachytherapy (IBT); Organs at Risk (OAR); Oncological profile of diagnoses

Introduction

Immediately after discovery of X-rays by Röntgen [1] as well as of radioactivity and radium by Becquerel as well as Madame Curie and her husband [2-4], Freund reported the first medical use of X-rays in a benign dermatological disease [5].

Through the following years, radiotherapy began to be established as one of the main treatment principles in malignant tumor disease [6-10]. From the beginning, two basic strategies were pursued and further developed:

1. Radiotherapy with X-rays from external site via a greater distance through the skin (percutaneous radiotherapy with great operating range, the so-called "external beam radiotherapy"=EBRT), and
2. Contact radiation by means of radioactive sources (radiation with short operating range, therefore "brachytherapy" derived from the Greek word βραχύς for short).

BT, which is the main focus of this overview, can be, therefore, considered a type of radiotherapy, which has been used for more than 100 years [11-14].

In contrast to the percutaneous photon-based radiation generated by X-ray tube or linear accelerator, the today’s BTs is based on photons generated by radioactive gamma decay(since generated...
by radioactive decay, it is called gamma radiation). This radiation has only a short operating range due to the significantly lower amount of energy providing the advantage that during therapeutic procedure, the surrounding organs (called "organs at risk" [OAR]) can be much better preserved than by a percutaneous radiation mode. On the other hand, BT requires a spatially not much extended rather close distance between radiation source and tumor lesion. To realize this, either special applicators (intraluminal BT), catheters, tubes or hole needles (interstitial BT) needs to be placed or inserted:

- Within or near the tumor lesion (definitive or primary radiotherapy),
- Into a postoperative (former) tumor bed, in existing (hole) spaces/lumens (e.g., esophagus, Bronchus, cervix) (or)
- In case of superficial mucosa or skin tumors, into moulages, which are adhered to the tumor surface?

Via the devices, radioactive source is transferred to or at the tumor lesion using After Loading (AL) procedure after previous 3D-based imaging and precise calculation of the appropriate dos(ages). Depending on the dose rate per time, "Low-Dose-Rate" (LDR), "Medium-Dose-Rate" (MDR) or "High-Dose-Rate" (HDR) BT is distinguished. According to this, the duration of the radiation is different, e.g., in "low-risk" prostate cancer encapsulated iodine or palladium seeds can be used as part of a LDR-BT, which provides the effective cumulative dose within only three months. In contrast, HDR-BT takes only several minutes.

Both strategies of radiation (EBRT and BT) have become clinical standard in the mean time. However, BT is used only for a restricted spectrum of indications in the majority of centres, in particular, in gynecological tumor lesions (carcinoma of the vagina, of the endometrium and cervix uteri as well as breast cancer, in the latter case as boost or in cases of local tumor recurrence) and prostate cancer. In addition, BT is also considered a potential standard procedure in superficial end luminal tumor lesions of the bronchial system or the esophagus.

Last but not least, brachytherapy is also part of the therapeutic spectrum for tumor lesions of otorhinolaryngology at several institutions of radiotherapy.

Without dispute, there is no sustainable therapeutic result achievable with no complete resection of the primary tumor lesion or even metastases, and derived from this, surgical resection has a great value in this concept.

In various tumor entities such as cancer of the pharynx, cervix, prostate and anus, it has been shown [15-18] that radiation and a combined radio-/chemotherapy can be considered an equivalent treatment alternative for curation of locally advanced non-metastasized tumor stages.

In case of
- Oligometastasized tumor stage (or)
- Local recurrence of the tumor lesion,

Local clearance of tumor growth can also result in a potential improvement of overall tumor prognosis in addition to a mitigation of tumor-associated symptoms.

For patients who are inoperable and unrespectable due to various reasons, numerous minimally invasive tumor-ablating therapy modes have been introduced and established in clinical practice [19-21], which broaden the spectrum of available options to treat cancer patients. In this context, Radio Frequency Ablation (RFA) [22-25] as thermoablative or interstitial brachytherapy (iBT) [26-30] as radioablative procedure need to be mentioned.

Taken together, beside oncosurgery as the undisputable gold standard for the treatment of solid tumor lesions in numerous tumor diseases there are effective alternatives and additive procedures.

The common aim is to achieve local tumor control but alternative treatment strategies are mainly used if surgical intervention is not the best choice due to various reasons.

However, there has been no broad consensus yet since for the majority of tumor diseases, prospective studies comparing the various alternative or additive approaches are rather rare.

Therefore, on one hand the novel minimally invasive measures need to be discussed in the interdisciplinary tumor board sessions and to be used adequately according to their therapeutic potential (in particular, if tumor resection is not a reasonable choice) and on the other hand, studies need to be initiated comparing the various therapeutic procedures to gain for appropriate evidence.

By means of modern tomographic imaging, it has become possible to reach almost each tumor lesion by means of a minimally invasive approach using diverse applicators such as catheters or hole needles and, thus, to put brachytherapy into effect.

In particular, for pulmonary and hepatic metastases of colorectal carcinomas and for hepatocellular carcinoma (HCC), effectiveness by radiotherapy modes has been detected with regard to local tumor control and overall tumor prognosis [31-34].

Most likely, indication profile will be extended due to ongoing clinical phase-II studies, e.g.,
- Use of iBT in renal cancer,
- Combination of radiotherapy with systemic therapy in cholangiocarcinoma (or)
- Feasibility and effectiveness of a hypo fractionated brachytherapy.


The aim of the manuscript is based on the overall positive experiences and the recent dynamic development of modern BT to provide an update on the today's options of this very specific and novel mode of tumor therapy. In particular, it is shown in which indications BT (spectrum of diagnoses) can be reasonably considered in addition to surgical and locally ablative procedures as well as novel concepts can be put into effect at the University Hospital of Magdeburg (Germany) in daily clinical practice. In detail,

1. It is described which specific procedures of BT (methodological profile) are used,
2. It is shown what case numbers can be achieved currently,
Table 1: Chronological overview of representative studies on brachytherapy.

<table>
<thead>
<tr>
<th>AUTHOR</th>
<th>Title of publication</th>
<th>Bibliographic data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grimm P et al.</td>
<td>Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostata Cancer Results Study Group.</td>
<td>BJU Int 2012; 109 (suppl): 22-29</td>
</tr>
</tbody>
</table>

3. Practical experiences are discussed obtained in clinical studies, (and)
4. Selective references from the literature are provided, (as well as)
5. Representative cases are reported.

General Treatment-associated Data

For an adequate, case-specific decision-making with regard to an appropriate indication and competent realization of the majority of BT, a confident interdisciplinary collaboration is basically required. In particular, this is important for the interstitial application (iBT), e.g.

1. Under ultrasound, CT or MRT guidance tumor lesion is larded with BT catheters (or)
2. Applicators are inserted into whole spaces under CT or ultrasound guidance (or)
3. After tumor debulking or postoperative imaging of the residual tumor lesion, catheters are placed within the tumor bed.

The conceptual idea is to
- achieve a maximally possible, i.e., acceptable tumor-damaging radiation (dose) but,
  Simultaneously,
- minimize radiation-induced side effects (e.g., irritable bowel syndrome, skin reaction etc.)

With curative, adjuvant, additive or palliative intention as well as the most promising fractionation modus (one session up to 30Gy, fractionation with 2 radiation sessions per day up to an overall dosage of 30-36Gy) by placement of local radiation sources via various access routes.

The interdisciplinary teams comprise radio oncologists, general and abdominal surgeons, otorhinolaryngologists, oral and maxillofacial surgeons, gastroenterologists, gynecologists, pulmologists and, in particular, interventional radiologists.

Overall Survey of Treatment Data

From 04/2006 to 12/2013, the number of BT increased steadily until 2009 and since then, it has been consolidated.

On average, 330-350 patients per year are currently treated, several of them with oligometastasized status are treated at various tumor sites resulting in a number of procedures (with regard to the treated tumor manifestation sites) of approximately 450.

The mean age of patients was 63.94 (range, 15-89) years; sex ratio (f: m) of iBT patients was 38.4:61.6% (overall including gynecological tumor sites resulting in a number of procedures (with regard to the treated tumor manifestation sites) of approximately 450.

Out of the 2,278 patients treated until 12/2013,
- 56% underwent iBT of the liver, lung etc.
- 36% were transferred from gynecological departments for an intraluminal, partially also additional Interstitial BT of the genitals,
- 8% were treated with interstitial BT or via moulagesat tumor sites of otorhinolaryngology, with Intraluminal (endobronchial, esophageal, anal or endobiliary) BT (and)
- 1 % underwent intraoperative radiation using the INTRABEAM device (Carl ZeissMeditec AG, Jena, Germany).

A substantial proportion of the iBT patients underwent multiple BT sessions at various tumor manifestation sites, finally resulting in a number of single applications of 3,117.
The comparison with data from the literature is almost not possible since the proportion of iBT for the treatment of metastases within various organs (lung, liver, kidney etc.) at the reporting institution is extraordinarily high.

The usually provided “standard”BT comprises (as mentioned above) mainly
- Prostate-associated HDR-BT or seed implantations,
- Gynecological and intraluminal applications (and)
- Interstitial treatment of tumor recurrence lesions, e.g., of breast cancer (Table 1).

Medical Discipline and Diagnosis-specific Treatment Experiences

Gynecology

Gynecology belongs to the classical field of this mode of radiotherapy to use BT in malignant gynecological diseases. Dominici is one of the pioneers in the field who worked first with radium capsules implanted intrauterinely in endometrial cancer [35]. Subsequently, intracervical and intrauterine applicators were developed and implanted [36-40].

Today, adjuvant vaginal BT depending on tumor stage according to FIGO classification alone or in combination with EBRT (BT, in particular, to reduce the risk for recurrent tumor growth at the vaginal stump) in endometrial cancer [41-43] as well as intracervical/interstitial application as part of definitive radiochemotherapy of cervical cancer [44,45] belong to standardized treatment protocols.

In addition, BT alone or in combination with percutaneous radiation and simultaneous chemotherapy can also be used, e.g.,
- In primary tumor lesions of the vagina [46-48] (or)
- In vulvar cancer for a preoperative or adjuvant therapeutic setting or as definitive treatment [49-51] predominantly with curative intention.

Through the investigation period, overall
- 474 patients with gynecological tumor lesions (except breast cancer) with 1,626 BT fractions were treated,
  * out of them, 85 patients with primary, inoperable cervical cancer,
- 358 endometrial cancer patients (and)
- 31 cases with vaginal or vulvar cancer or recurrent tumor growth of uterine neoplasms.

Head-and-neck tumor lesions

Tumor lesions of the head and neck can be considered a heterogeneous group of patients; therefore, a uniform superordinated treatment concept cannot be easily defined. Currently, there is only a German S3-guideline existing for floor-of-mouth cancer [55], however, there has been a study-based consensus with regard to the role of percutaneous radio-/radiochemotherapy with adjuvant and definitive intention [56-58].

In contrast, a possible interstitial BT without external beam radiation therapy (EBRT) or boosting is frequently not discussed or offered though BT has a substantial value based on several studies [59] with regard to local tumor control and improvement of the overall prognosis [60]. The GEC-ESTRO group (Groupe Européen de Curiethérapie and the European Society for Radiotherapy &Oncology) recommends, therefore, using BT at head and neck [61].

Tumor lesions of the head and neck can be considered a heterogeneous group of patients; therefore, a uniform superordinated treatment concept cannot be easily defined. Currently, there is only a German S3-guideline existing for floor-of-mouth cancer [55], however, there has been a study-based consensus with regard to the role of percutaneous radio-/radiochemotherapy with adjuvant and definitive intention [56-58].

In contrast, a possible interstitial BT without external beam radiation therapy (EBRT) or boosting is frequently not discussed or offered though BT has a substantial value based on several studies [59] with regard to local tumor control and improvement of the overall prognosis [60]. The GEC-ESTRO group (Groupe Européen de Curiethérapie and the European Society for Radiotherapy &Oncology) recommends, therefore, using BT at head and neck [61].

Basically, BT can be used in the following situations:

1. As alternative for surgical resection of locally restricted T1/2 tumor lesions, in particular, at the lips, cheeks and oral cavity [62-64],
2. As addition to percutaneous radiation providing a local dosage escalation in advanced inoperable tumor lesions or after R1 resections and lack of a promising option for repeated resection [65] (and)
3. In recurrent tumor growth at the local tumor site or within lymph nodes and in patients pretreated with
Percutaneous radiotherapy [66-70].

At the University Hospital of Magdeburg (Germany), locally restricted tumor lesions are usually resected, boosting is used via percutaneous access route due to the available modern radiotherapy techniques (e.g., tomotherapy, intensity-modulated radiotherapy=IMRT).

Derived from this, HDR-BT has been predominantly offered to and used in cases with recurrent tumor growth or with palliative intention as well as with previous radiotherapy. Overall, 18 patients were treated from 06/2006 to 12/2013 (Figure 1-7),

- after patient-made production of individual moulages,
- after surgical intervention aiming for tumor-debulking and in unrespectable tumor growth, respectively,

With interstitial BT. The doses varied from 20 to 36Gy with single doses of 2.5-3Gy twice a day and a minimal interruption of 6 hours between the single fractions.

Brachytherapy in intraluminal tumor lesions

Intraluminal BT applications may reasonably add multimodal treatment concepts with curative or palliative intention [71,72]. In the following tumor sites, BT has been proven:

- Bronchial [73-75],
- Esophageal [76, 77],
- Biliary [78,79] (and)
- Anal [80].

BT plays, in particular, an additional role to the
- Primary surgical approach,
- Percutaneous radiation,
- Combination with palliative chemotherapy, and
- Palliative intention in pretreated patients with percutaneous radiotherapy.

At the reporting institution, overall 21 patients underwent BT at the tumor sites as listed above from 2006 to 2013:

- The largest proportion comprised patients with recurrent tumor growth of esophageal cancer,
- 4 cases with locally restricted but despite this unrespectable cholangiocarcinoma (and)
- The remaining cases were successfully treated with palliative intention aiming for local tumor control.

Interstitial brachytherapy (iBT) for treatment of local tumor lesions and metastases.

In addition to the described indications, metastases within parenchymatous organs (liver, lung, and kidney) or even soft tissue and lymph node metastases are suitable for iBT. In detail, needles or BT catheters are precisely inserted – either intraoperatively or under CT- or MRT-based fluoroscopy guidance - into malignant tumor masses. Using this approach, lower numbers of thoracic/pulmonary, hepatic or abdominal metastases but also primary liver tumors or soft tissue sarcomas can be treated.

Feasibility, safety and benefit of this minimally invasive type of radiation has been proven by numerous retro- and prospective studies and analyses in the mean time [26,31,81,82], which thus occupies an established place in the reporting department.

This has become possible by the close collaboration with interventional radiologists and all the transferring oncological disciplines in medicine, in particular, with abdominal surgery.

Primary aim was to achieve local symptom control by radiation-induced cytoreduction with palliative intention at the beginning [26] but the study results showed that in numerous cases, a sustainable local control sometime even an improvement of the overall prognosis became possible.

In the phase-II study by Ricke et al. [83], local control rate after iBT of overall 73 patients (subdivided into three various groups of doses [one-time doses per group: 15, 20 or 25 Gy]) with hepatic metastases of colorectal cancer in total was investigated. The mean local control rate of all groups was 34 months(according to Kaplan–Meier assessment) whereby it significantly increased – as expected – with higher dose of radiation (25.6, 31.1 and 46.6 months, respectively). Mohnike et al [84]. Showed a significantly better survival in 83 patients with HCC who had undergone prospective BT compared (by "matched-pair" analysis) with a group of patients with no radiation.

A further study reported on local 1- and 2-years control rates of 93% and 82% in secondary and 86% and 79%, respectively, in primary solitary but unrespectable malignant neoplasms of the lung [85].

**Representative Case Reports**

**Case 1 (Figures 8-11)**

Medical history: 74-year old male patient with symptomatic metastasis of rectal cancer localized at the left iliac muscle.

10/2006 – deep anterior resection with TME and creation of a protective ileostoma, pT3a pN1 (14/81) cM0 R0 G2

Until 04/2007 – adjuvant radio chemotherapy with 5-FU ad 54 Gy
followed by 4 cycles of Chemotherapy alone with 5-FU
06/2007 – Recreation of gastrointestinal passage
01/2011 – Recurrent tumor growth at the left iliac muscle
Until 04/2012 – 2nd-and 3rd-line chemotherapy
- Result: partial response
- Side effect: polyneuropathy and -foot syndrome
05/2012 – local radiotherapy because of pain ad 14.4Gy – result:
“Stable disease” (SD)
12/2012 – subsequently SD but increasing pain.

Therapeutic decision-making after interdisciplinary board
presentation of the case: Surgical intervention aiming for a possibly
radical but function-preserving tumorreduction and following local
BT taking into account the previous radiation exposition and dose.

Further clinical course:
03-04/2013 – Tumor debulking+ postoperative fractionated iBT
ad 18/6Gy at the R2 site
10/2013 – distinct reduction of the treated tumor volume and
the pain, advanced tumor growth at the peripheral site of the treated
 tumor region

11/2013 – repeated, locally restricted one-time iBT taking into
account the exposure due to pre-radiation ad 13Gy
08/2014 – Recurrent tumor growth within the surrounding tissue
with infiltration of the right ileal
Bone: “Involved-field” EBRT taking into account the exposure
due to pre-radiation ad 20/4Gy.

Result: At the time of increasing symptoms, patient denied
repeated chemotherapy because of the persisting side effects. Since
distant metastases could be excluded, a local ablation appeared reasonable. High-dose iBT allowed – after surgical R2 tumor resection
– a completion of ablation.

Because of the 2-times prior percutaneous charge, repeated
EBRT would have been associated with significantly higher risk of a
damage of surrounding risk structures (OAR) and lower effectivity
(fractionation).

Furthermore, locally restricted iBT allowed a repeated radiation
therapy of the neighboring regions which showed metastases during
further clinical course.

Final assessment: Overall, a distinct improvement of the partially
considerable symptoms could be achieved by an interdisciplinary
coordinated local therapy.

Case 2 (Figures 10-12)
Medical history: 33-years old patient with superior vena-cava
compression syndrome due to a synovial cell sarcoma with metastases
in the lung and lymph nodes, G III.

09/2004 Solitary primary tumor lesion at the left heel
leading to amputation of the left calf
12/2005 Primary diagnosis of pulmonary metastases
leading to right-sided segmental resection
11/2005-02/2006 3 cycles of chemotherapy with
Ifosfamid/Adriamycin
02/06 Stereotactic RT ad 30Gy per single dosesof 10Gy because
of recurrent tumor growth within the left paracardial region
In the mean time, pro- and retrospective studies provided evidence that in part more than a palliative effect can be achieved. In particular, patients with metastases of colorectal origin [83] but also those with locally restricted HCC [34,84] may benefit from this approach with a prolongation of survival. A basic prediction for the future is that the majority of complications has been micro invasively and conservatively treated since 2006.

Discussion

The value of radiotherapy established until today as part of curative and palliative tumour therapy strategies cannot longer be denied even if the use of it is possibly ranked inferior to best supportive care and beyond primary therapeutic concepts in a certain proportion of oncologists.

While the options of percutaneous radiation techniques are known and present as well as discussed in the media and tumor board conferences throughout the country, BT is rather underestimated. However, advantages are obvious in case of a clearly defined indication, e.g.

- High, locally applicable tumor-damaging dose,
- Better preservation of the surrounding OAR by a steep dose gradient (and)
- Shorter hospital stay, since over a few days a sufficient dose can be applied.

In the mean time, pro- and retrospective studies provided evidence that in part more than a palliative effect can be achieved. In particular, patients with metastases of colorectal origin [83] but also those with locally restricted HCC [34,84] may benefit from this approach with a prolongation of survival. A basic prediction for the broad use of brachytherapeutic interventions is an interdisciplinary collaboration.
-Adapted to patients' needs and tumor-specific finding(s),
-Related to the specific tumor entity and stage,
-According to established therapeutic experiences and proven modi of radiation to exhaust a sufficient, (neo-) adjuvant, additive or palliative therapeutic effect.

In addition, it has been shown that in many cases BT can be considered – from the perspective of health economy – a cost-effective but despite this a highly effective treatment alternative in the age of a rather increasingly cost-intensive tumor therapy, which broadens the spectrum of radio oncology.

**Conclusion**

Gold standard of local ablation was and is surgical resection. A certain percentage of (oligo-) metastasized patients can not undergo surgical intervention or tumor mass is unrespectable from a functional and tumor biological perspective. These patients can nevertheless treated with local ablation since in addition to surgical intervention (resection), there has been a number of non- and minimally invasive techniques available. These procedures can be subdivided into thermo-, chemo- and radio-ablating methods and have been multiply proven in prospective and retrospective studies with regard to safety, effectiveness and side effect rate [92-100].

RFA is currently the best validated method, which – if the metastasis is not bigger than 3cm in diameter – can be, in particular, in the liver, and is considered a reasonable alternative to surgical resection resulting in a very similar, i.e., low tumor recurrence rate (3.5 vs. 6 % per lesion). In larger metastases, surgical resection is superior (7.4 vs. 14.5 %) [101]. Under these circumstances iBT used in radiotherapy routine for decades can reasonably add the spectrum of indications and therapeutic modalities.

Data obtained in phase-II studies showed that in case of sufficient tumor-surrounding dose application, local tumor recurrence rate is approximately.
- 6.5 % in liver metastases of breast cancer [82],
- 5 % in liver metastases of colorectal origin [83] (and)
- 9 % and 14 / 7 % in primary and secondary malignant neoplasms of the lung [85].

In addition, Mohnike et al. [32] was able to demonstrate a significant improvement of survival in patients with versus cases without BT of locally advanced HCC manifestation.

A successful iBT requires a close interdisciplinary cooperation between radio oncologists, interventional radiologists and all oncological disciplines in medicine.

Finally, the clue for a broad use of all available oncological therapeutic options is their profound knowledge on
-the appropriate indications and possible complications,
-the indicated differential therapy,
-Methodological strengths and weaknesses obtained from individual

* Case-based experiences (and)

**References**


Submit your Manuscript  www.austinpublishinggroup.com


